PCM
GLUE icon

Prelude Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Prelude Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$715K Buy
+43,473
New +$831K 0.05% 390
2025
Q4 		– Sell
-10,202
Closed -$75.6K – 1393
2025
Q3 		$75.6K Buy
+10,202
New +$54K 0.01% 1078

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Prelude Capital Management's GLUE Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 43,473 shares worth $715K. The stake represents 0.05% of the portfolio and ranks #390 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in GLUE as recently as Q3 2025.

Prelude Capital Management first reported a position in GLUE in Q3 2025 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Prelude Capital Management held 43,473 shares of Monte Rosa Therapeutics worth $715K as of Q1 2026.
  • Monte Rosa Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.05% of Prelude Capital Management's portfolio in Q1 2026, its #390 holding.
  • Prelude Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.